Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at HC Wainwright from $70.00 to $118.00. They now have a "buy" rating on the stock.
LowReport
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at HC Wainwright from $70.00 to $118.00. They now have a "buy" rating on the stock.
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $83.00 price target on the stock, up previously from $75.00.
LowReport
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $83.00 price target on the stock, up previously from $75.00.
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Scotiabank from $62.00 to $70.00. They now have a "sector outperform" rating on the stock.
LowReport
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Scotiabank from $62.00 to $70.00. They now have a "sector outperform" rating on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: